Substantial delays in clinical data published by the European Medicines Agency – a cross sectional study
Open Access
- 12 March 2022
- journal article
- research article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 146, 68-76
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patientsPLOS ONE, 2017
- Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document AnalysisPLOS Medicine, 2016
- Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trialsTrials, 2016
- Extent of Non-Publication in Cohorts of Studies Approved by Research Ethics Committees or Included in Trial RegistriesPLOS ONE, 2014
- Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publicationsBMJ, 2014
- Increasing value and reducing waste: addressing inaccessible researchThe Lancet, 2014
- Reducing waste from incomplete or unusable reports of biomedical researchThe Lancet, 2014
- Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reportsBMJ Open, 2013
- Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publicationsBMJ, 2011
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004